Vanderbilt-Ingram Cancer Center created an APP-led outpatient clinic for bispecific antibody therapies, safely moving high-risk step-up dosing out of the inpatient setting. The program saved 137 of 192 recommended inpatient monitoring days, reduced inpatient utilization, and improved quality of life for patients receiving novel therapies.